Celixir plc news
Stratford-upon-Avon, UK: April, 6 2020 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was successfully dosed in the Company’s Heartcel clinical trial of its novel iMP cells in patients with cardiomyopathy on
March 16, 2020 and is now in the follow up stage. CLXR-001 is a novel formulation that allo
Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines
- Promising cancer gene therapy programme using small interfering RNA (siRNA)
- Data from in vitro study published in PLOS journal
Stratford-upon-Avon, UK, 13 May 2019 – Celixir, a privately-owned company discovering and developing life-saving advanced the
- FDA IND and UK MHRA CTA approval both achieved in H1 2018
- Potentially pivotal heart failure trial of up to 250 patients in the UK and US
Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel, its immune-modulatory progenitor (iMP) cell therapy for the treatment of adult heart
Hockey for Heroes, a supporting charity of Help for Heroes who raise money to help our injured and fallen Heroes, today announces a multi-thousand pound sponsorship renewal with Celixir, a leading British Cell Therapy company.
Celixir continues as the charity’s main shirt sponsor for 2018-19, enabling Hockey for Heroes to expand its program to enable injured veterans to take part in adaptive sports and rehabilitation.
“Hockey for Heroes are honoured to be supported
Celixir, a private company discovering and developing life-saving cell therapies, announces the appointment of Dr Mubasher Sheikh (Chairman), Professor Fiona Murray CBE, Professor Gary Pisano, Conor Kehoe and Professor Sir Martin Evans as Non-Executive Directors.
Celixir recently announced approval of a clinical trial application from the UK’s Medicines and Healthcare Products Regulatory Agency to initiate a potentially pivotal Phase IIb human clinical trial with its Heartcel&tr
Adult heart failure trial to complete in 2020 with potential market entry in 2021
Trial to be conducted at Imperial College London’s Royal Brompton, UK
Celixir, a private company discovering and developing lifesaving regenerative medicines, today announced it has received formal clinical trial application (CTA) approval from the Medicines and Healthcare Products Regulatory Agency to initiate a Phase IIb human clinical trial with its Heartcel medicine for t
Celixir (formerly Cell Therapy Limited) today announced the formation of the Innovative Cardiovascular Medicines Collaboration. The Collaboration includes world-leading expertise in cardiac research and clinical development, with the purpose of better understanding the basis for cardiac regeneration.
The Collaboration will be jointly led by Professor Kim Fox, Consultant Cardiologist and Professor of Cardiology at Imperial College and Professor Sir Martin Evans, No
Celixir, a leading British biotechnology company delivering breakthrough regenerative medicines, has today rebranded from Cell Therapy. The change reflects the company’s continued commitment to discovering, developing and delivering life-altering regenerative medicines, and transforming patient care.
“The name Celixir combines ‘Cell’ with the Latin root word elixir to convey our vision to develop curative regenerative medicines”, said Ajan Reginald, Chief
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global manufacturing responsibilities. Under the terms of the agreement, CTL receives a £12.5 milli